These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9723243)

  • 1. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 2. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 3. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 4. Variability of Sandimmune pharmacokinetics in renal transplant patients.
    Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
    Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
    Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
    Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
    Markell MS; Homel P; Sumrani N; Hong JH; Distant DA; Miles AM; Sommer BG; Friedman EA
    Transplant Proc; 1998 Aug; 30(5):1980-2. PubMed ID: 9723360
    [No Abstract]   [Full Text] [Related]  

  • 7. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
    Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
    Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
    [No Abstract]   [Full Text] [Related]  

  • 8. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
    Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
    Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.
    Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY
    Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
    Suh BY; Kwun OS; Kwun KB
    Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
    Crocker J; Renton K; Wade A; McLellan H; Acott P
    Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
    [No Abstract]   [Full Text] [Related]  

  • 13. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
    Chueh SC; Liao CH; Lai MK
    Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug monitoring of mycophenolic acid in the early period after renal transplantation.
    Krumme B; Wollenberg K; Kirste G; Schollmeyer P
    Transplant Proc; 1998 Aug; 30(5):1773-4. PubMed ID: 9723276
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients?
    Einollahi B; Rostami Z; Kalantar E; Lessan-Pezeshki M; Pourfarziani V; Nemati E
    Transplant Proc; 2011 Mar; 43(2):488-90. PubMed ID: 21440741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
    Wong HS; Morad Z
    Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
    [No Abstract]   [Full Text] [Related]  

  • 17. Preservation of renal function during maintenance therapy with cyclosporine.
    Serón D; Moreso F
    Transplant Proc; 2004 Mar; 36(2 Suppl):257S-260S. PubMed ID: 15041349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients.
    Einecke G; Mai I; Diekmann F; Fritsche L; Neumayer HH; Budde K
    Transplant Proc; 2002 Aug; 34(5):1738-9. PubMed ID: 12176557
    [No Abstract]   [Full Text] [Related]  

  • 19. Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity?
    Domínguez J; Tomic A; Norambuena R
    Transplant Proc; 2001; 33(7-8):3120-1. PubMed ID: 11750341
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.